Risankizumab, an antibody that binds to the p19 subunit of IL-23, inhibiting its action (168), has been approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn’s disease in adults. The gene discussed is IL23A; the disease is psoriasis vulgaris.